文献速递白血病

伊布替尼联合维奈克拉双靶点抑制治疗急性髓系白血病

Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
PubMed 文献 · Leukemia · 2020-02-24

研究通过体外功能筛选发现,BTK抑制剂伊布替尼联合BCL2抑制剂维奈克拉(IBR+VEN)对原代AML患者标本、AML细胞系及小鼠异种移植模型均显示增强疗效。在651例血液恶性肿瘤患者中,IBR+VEN敏感性在CLL和AML标本中与特定遗传和表型特征相关,AML中11q23 MLL重排样本高度敏感。

要点

  • IBR+VEN联合方案在AML原代标本、细胞系及小鼠模型中显示增强疗效。
  • 11q23 MLL重排的AML样本对IBR+VEN高度敏感。
  • 体外敏感性降低的样本中IL-10信号通路富集。

核心结论

  • 伊布替尼联合维奈克拉(IBR+VEN)可能成为AML的有效治疗选择。

研究设计与样本

  • 采用体外功能筛选 assay,并在原代AML患者标本、AML细胞系及小鼠异种移植模型中验证。
  • 扩展分析纳入651例血液恶性肿瘤患者标本,评估IBR+VEN敏感性与遗传及表型特征关联。

主要发现

  • IBR+VEN对原代AML患者标本、AML细胞系及小鼠AML异种移植模型显示增强疗效。
  • 在651例血液恶性肿瘤中,IBR+VEN敏感性在CLL和AML标本中与特定遗传和表型特征相关。
  • AML样本中,11q23 MLL重排对IBR+VEN高度敏感。
  • 体外敏感性降低的患者样本中,差异表达基因分析显示IL-10信号通路优先富集。

临床怎么用

  • IBR+VEN联合方案可能为AML患者提供新的治疗策略,尤其对11q23 MLL重排AML值得进一步临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) results from the enhanced proliferation and impaired differentiation of hematopoietic stem and progenitor cells. Using an ex vivo functional screening assay, we identified that the combination of the BTK inhibitor ibrutinib and BCL2 inhibitor venetoclax (IBR + VEN), currently in clinical trials for chronic lymphocytic leukemia (CLL), demonstrated enhanced efficacy on primary AML patient specimens, AML cell lines, and in a mouse xenograft model of AML. Expanded analyses among a large cohort of hematologic malignancies (n = 651 patients) revealed that IBR + VEN sensitivity associated with selected genetic and phenotypic features in both CLL and AML specimens. Among AML samples, 11q23 MLL rearrangements were highly sensitive to IBR + VEN. Analysis of differentially expressed genes with respect to IBR + VEN sensitivity indicated pathways preferentially enriched in patient samples with reduced ex vivo sensitivity, including IL-10 signaling. These findings suggest that IBR + VEN may represent an effective therapeutic option for patients with AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Eide CA, Kurtz SE, Kaempf A, et al. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. Leukemia. 2020. PMID: 32094466. doi:10.1038/s41375-020-0764-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。